Whitehawk Therapeutics, Inc.

WHWK Nasdaq SEC CIK 1422142
Follow Whitehawk Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$16.6M +68.4% vs same quarter last year
EPS, diluted −$0.20 +73.7% vs same quarter last year
Operating cash flow −$14.5M +72.6% vs same quarter last year
Revenue by quarter
$7.2M
$7.2M
$7.1M
$0
$0
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$7.1M−$20.6M
FY24$26M−$63.7M
FY23$24.4M−$65.8M
FY22$15.2M−$60.5M
FY21$14M−$110.1M
FY20$14M−$3.5M
FY19$0−$23.3M
FY18$20.2M−$10.4M
FY17-−$21.4M
FY16-−$17M
FY15-−$31.4K
FY14-−$30.8K
FY13-−$28.7K
FY12-−$27.4K
FY11-−$27.2K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2589.4%−1601.1%−288.3%
FY2488.4%−259.6%−245.1%
FY2388.5%−295.4%−270%
FY2291.2%−411.9%−397.7%
FY21100%−794.4%−786.4%
FY20-−18.2%−24.8%
FY19---
FY18-−55.5%−51.6%
FY17---
FY16---
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$98M
FY24−$61.2M
FY23−$63.6M
FY22−$50.1M
FY21−$22.5M
FY20−$12.7M
FY19−$24.1M
FY18−$5.8M
FY17−$18.9M
FY16−$137.8K
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Whitehawk Therapeutics
  • Healthcare median
−800%−600%−400%−200%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearWhitehawk TherapeuticsHealthcare median
FY25−288.3%−40.6%
FY24−245.1%−60.7%
FY23−270%−97.1%
FY22−397.7%−128.5%
FY21−786.4%−129.2%
FY20−24.8%−136.5%
FY19-−133.7%
FY18−51.6%−173.4%
FY17-−176.7%
FY16-−164.8%
FY15-−183.4%
FY14-−133%
FY13-−88.5%
FY12-−87.4%
FY11-−76.3%

News

No stories filed under Whitehawk Therapeutics yet - coverage appears here as the news feed clusters it.